SyVento BioTech, as a leading CDMO specialized in lipid-based nanocarriers technology and production, together with aseptic clinical fill&finish, is excited to announce its participation in PHASE 2024, a premier event for the medical biotechnology industry. Taking place between 27th and 29th of August.
PHASE 2024, as one of the most relevant forums of Polish medical biotechnology, brings together key stakeholders, including investors, entrepreneurs, and scientists, to discuss the latest advancements and challenges in the field.
SyVento BiotTech’s CTO, Dominik Lipka, PhD Eng., will take part in the Oxford-style debate on “Innovative drugs or generics?” scheduled for August 27th at 13:00. This high-profile discussion will delve into critical aspects of innovative and generic drug development and the industry’s future.
As a CDMO with a comprehensive service offering, SyVento BioTech is committed to driving innovation in lipid-based formulations for pharmaceutical products, including RNA-based therapeutics. Our unique end-to-end capabilities, from mRNA synthesis to cGMP production, enable us to deliver tailored solutions for our clients.
We invite you to follow us on LinkedIn and X for more updates!
